Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00238
|
|||||
| Drug Name |
Leucovorin
|
|||||
| Synonyms |
5-formyltetrahydrofolate; Citrovorum factor; Folinic acid
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Colorectal cancer [ICD11: 2B91] | Approved | [1] | |||
| Therapeutic Class |
Vitamins
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H23N7O7
|
|||||
| Canonical SMILES |
C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
|
|||||
| InChI |
InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12?,13-/m0/s1
|
|||||
| InChIKey |
VVIAGPKUTFNRDU-ABLWVSNPSA-N
|
|||||
| CAS Number |
CAS 58-05-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 473.4 | Topological Polar Surface Area | 216 | ||
| Heavy Atom Count | 34 | Rotatable Bond Count | 9 | |||
| Hydrogen Bond Donor Count | 7 | Hydrogen Bond Acceptor Count | 10 | |||
| XLogP |
-1.2
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:15640
|
|||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| MRP3 | Transporter Info | Multidrug resistance-associated protein 3 | Substrate | [3] | ||
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [4] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | MRP3 | Transporter Info | Km = 1740 microM | Human embryonic kidney cells (HEK293)-MRP3 | [3] | |
| MRP4 | Transporter Info | Km = 640 microM | Spodoptera frugiperda (Sf9) cells-MRP4 | [4] | ||
| References | ||||||
| 1 | Leucovorin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54. | |||||
| 3 | Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. | |||||
| 4 | Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.